Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19027486 | 0.92 | DRD2 (0.45) | KMT2ADRD2ALDH1A1GFERMALT1 | |
| SCHEMBL30271521 | 0.91 | TDP1 (0.47) | KMT2ADRD2ALDH1A1TDP1STK17B | |
| SCHEMBL16065264 | 0.90 | TDP1 (0.49) | DRD2ALDH1A1TDP1STK17BSTK17A | |
| SCHEMBL17407009 | 0.90 | TDP1 (0.49) | DRD2ALDH1A1TDP1STK17BSTK17A | |
| SCHEMBL30293315 | 0.90 | TDP1 (0.49) | DRD2ALDH1A1TDP1STK17BSTK17A | |
| SCHEMBL13975444 | 0.85 | LMNA (0.47) | KMT2AMAPTDRD2ALDH1A1GFER | |
| SCHEMBL19558618 | 0.84 | ALDH1A1 (0.41) | KMT2ADRD2ALDH1A1GFERMALT1 | |
| SCHEMBL13740008 | 0.84 | ALDH1A1 (0.41) | KMT2ADRD2ALDH1A1GFERMALT1 | |
| SCHEMBL16899828 | 0.84 | ALDH1A1 (0.41) | KMT2ADRD2ALDH1A1GFERMALT1 | |
| SCHEMBL16020336 | 0.83 | ALDH1A1 (0.41) | KMT2ADRD2ALDH1A1GFERMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12240840-B2 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020273-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | TYK2, IFNG, JAK3 | KMT2A 1356/4885MAPT 2757/4885PKM 1565/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | KMT2A 1216/4885MAPT 3763/4885PKM 4403/4885 |
| US-12240840-B2 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha | TYK2, IFNG, JAK3 | KMT2A 1356/4885MAPT 2757/4885PKM 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.